GATC Health Featured in Drug Discovery World: How AI and multiomics are accelerating drug discovery

GATC Health Featured in Drug Discovery World

“How AI and multiomics are accelerating drug discovery”

We are pleased to share that GATC Health was featured in the latest issue of Drug Discovery World. The article highlights our advanced AI-driven platform and its transformative potential to accelerate drug discovery, improve success rates, and address critical unmet medical needs.

For the article, DDW Editor Reece Armstrong spoke with Tyrone Lam, Chief Business Officer (CBO) at GATC Health, about how multiomics and AI can advance drug discovery for complex diseases, citing the company’s efforts in opioid use disorder (OUD).

“At GATC, we use our proprietary AI platform, called Multiomics Advanced Technology (MAT), to simulate human biology based on multiomic inputs,” noted Lam.“This allows us to model drug-disease interactions, predict efficacy and toxicity, and optimise compounds in silico before a molecule ever reaches a petri dish or animal model. It’s about shifting drug development from empirical topredictive science.”

This editorial coverage underscores growing awareness of our technology within the global life sciences community and reflects the meaningful progress we are making toward redefining the future of healthcare.

We encourage you to read the full story in Drug Discovery Worldto gain deeper insight into how GATC Health is driving innovation in drug development.

About GATC Health

GATC Health is a techbio company revolutionizing drug discovery and development through its Multiomics Advanced Technology™ (MAT) platform. Trusted by the world’s largest insurance marketplace, the company serves biopharma, healthcare, and investment partners by providing predictive analyses of molecules for safety and efficacy, as well as creating novel intellectual property and optimizing clinical strategies. MAT simulates complex human biology to predict how drugs will perform in the body, achieving 86% sensitivity and 91% specificity in a university validation study. By uniting advanced AI, multiomics, and predictive modeling, GATC is accelerating breakthroughs and reducing costly late-stage failures to bring safer, more effective therapies to patients worldwide. For more information, visit www.gatchealth.com.